Summary: Peginterferon/Ribavirin-Experienced, Genotype 5 or 6 Patients With or Without Compensated Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

Peginterferon/Ribavirin-Experienced, Genotype 5 or 6 Patients With or Without Compensated Cirrhosisa

RECOMMENDED DURATION RATING
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b for patients without cirrhosis 8 weeks IIa, B

Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b for patients with compensated cirrhosis 12 weeks I, B
Daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks IIa, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) 12 weeks IIa, B
a For decompensated cirrhosis, please refer to the appropriate section.
​b This is a 3-tablet coformulation. Please refer to the prescribing information.

 

Last update: 
September 21, 2017
Top